These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 35224495)
1. An overview of the development of EED inhibitors to disable the PRC2 function. Liu KL; Zhu K; Zhang H RSC Med Chem; 2022 Jan; 13(1):39-53. PubMed ID: 35224495 [TBL] [Abstract][Full Text] [Related]
2. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs. Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670 [TBL] [Abstract][Full Text] [Related]
3. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer. Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687 [TBL] [Abstract][Full Text] [Related]
4. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance. Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198 [TBL] [Abstract][Full Text] [Related]
5. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns. Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628 [TBL] [Abstract][Full Text] [Related]
6. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer. Martin MC; Zeng G; Yu J; Schiltz GE J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516 [TBL] [Abstract][Full Text] [Related]
7. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment. Cook N; Chen J; Zhou J; Wu D Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341 [TBL] [Abstract][Full Text] [Related]
8. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594 [TBL] [Abstract][Full Text] [Related]
9. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2. Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470 [TBL] [Abstract][Full Text] [Related]
10. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-323-3p regulates the activity of polycomb repressive complex 2 (PRC2) via targeting the mRNA of embryonic ectoderm development (Eed) gene in mouse embryonic stem cells. Zhang Y; Teng F; Luo GZ; Wang M; Tong M; Zhao X; Wang L; Wang XJ; Zhou Q J Biol Chem; 2013 Aug; 288(33):23659-65. PubMed ID: 23821546 [TBL] [Abstract][Full Text] [Related]
13. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235 [TBL] [Abstract][Full Text] [Related]
14. Inner workings and regulatory inputs that control Polycomb repressive complex 2. O'Meara MM; Simon JA Chromosoma; 2012 Jun; 121(3):221-34. PubMed ID: 22349693 [TBL] [Abstract][Full Text] [Related]
15. Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation. Montgomery ND; Yee D; Montgomery SA; Magnuson T J Mol Biol; 2007 Dec; 374(5):1145-57. PubMed ID: 17997413 [TBL] [Abstract][Full Text] [Related]
16. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116 [TBL] [Abstract][Full Text] [Related]
17. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Xu C; Bian C; Yang W; Galka M; Ouyang H; Chen C; Qiu W; Liu H; Jones AE; MacKenzie F; Pan P; Li SS; Wang H; Min J Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19266-71. PubMed ID: 20974918 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma. Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Polycomb Repressive Complex 2 activity reduces trimethylation of H3K27 and affects development in Arabidopsis seedlings. Ruta V; Longo C; Boccaccini A; Madia VN; Saccoliti F; Tudino V; Di Santo R; Lorrai R; Dello Ioio R; Sabatini S; Costi R; Costantino P; Vittorioso P BMC Plant Biol; 2019 Oct; 19(1):429. PubMed ID: 31619182 [TBL] [Abstract][Full Text] [Related]
20. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]